Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BEVACIZUMAB Cause Peripheral arterial occlusive disease? 32 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 32 reports of Peripheral arterial occlusive disease have been filed in association with BEVACIZUMAB (JOBEVNE). This represents 0.0% of all adverse event reports for BEVACIZUMAB.

32
Reports of Peripheral arterial occlusive disease with BEVACIZUMAB
0.0%
of all BEVACIZUMAB reports
5
Deaths
11
Hospitalizations

How Dangerous Is Peripheral arterial occlusive disease From BEVACIZUMAB?

Of the 32 reports, 5 (15.6%) resulted in death, 11 (34.4%) required hospitalization, and 1 (3.1%) were considered life-threatening.

Is Peripheral arterial occlusive disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BEVACIZUMAB. However, 32 reports have been filed with the FAERS database.

What Other Side Effects Does BEVACIZUMAB Cause?

Off label use (12,094) Death (8,493) Diarrhoea (4,911) Disease progression (4,653) Fatigue (4,572) Nausea (4,357) Hypertension (4,309) Anaemia (3,221) Vomiting (3,193) Neutropenia (2,875)

What Other Drugs Cause Peripheral arterial occlusive disease?

NILOTINIB (319) METHOTREXATE (120) ADALIMUMAB (116) RIVAROXABAN (101) PONATINIB (90) IMATINIB (86) ASPIRIN (77) ATORVASTATIN (70) METOPROLOL (70) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (63)

Which BEVACIZUMAB Alternatives Have Lower Peripheral arterial occlusive disease Risk?

BEVACIZUMAB vs BEVACIZUMAB-AWWB BEVACIZUMAB vs BEVACIZUMAB-BVZR BEVACIZUMAB vs BEVACIZUMAB-MALY BEVACIZUMAB vs BEXAROTENE BEVACIZUMAB vs BEYAZ

Related Pages

BEVACIZUMAB Full Profile All Peripheral arterial occlusive disease Reports All Drugs Causing Peripheral arterial occlusive disease BEVACIZUMAB Demographics